Drug intelligence / Profile preview

C-DIM5

Development stage
Unknown
Lead developer
Colorado State University
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

C-DIM5 is a synthetic small molecule belonging to the family of para-phenyl–substituted diindolylmethanes. It acts as an agonist for the orphan nuclear receptor Nur77 and also recruits Nurr1 in neural cells. The neuroprotective and anti-inflammatory efficacy is mediated through upregulation of Nur77 mRNA, suppression of neuroinflammatory genes, and inhibition of NF-κB–dependent expression of inflammatory and apoptotic targets. C-DIM5 prevents nuclear export of Nur77 and recruits Nurr1 to the nucleus, leading to transrepressive effects on inflammatory signaling. It has demonstrated efficacy in preventing loss of dopaminergic neurons in mouse models of Parkinson’s disease and can induce apoptosis in colon cancer cells. Administration is typically oral, and its pharmacokinetic profile has been studied in murine models[1][4][5][7].

Other names
1,1-bis(3′-indolyl)-1-(p-methoxyphenyl)methane
02

Targets

NR4A1 (Nuclear receptor subfamily 4 group A member 1)RELA (Nuclear Factor Kappa B Subunit p65)NR4A2 (Nuclear receptor subfamily 4 group A member 2)

Beyond the preview

Go deeper on C-DIM5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-DIM5.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call